SG11201505930TA - Porcine parvovirus 5b, methods of use and vaccine - Google Patents

Porcine parvovirus 5b, methods of use and vaccine

Info

Publication number
SG11201505930TA
SG11201505930TA SG11201505930TA SG11201505930TA SG11201505930TA SG 11201505930T A SG11201505930T A SG 11201505930TA SG 11201505930T A SG11201505930T A SG 11201505930TA SG 11201505930T A SG11201505930T A SG 11201505930TA SG 11201505930T A SG11201505930T A SG 11201505930TA
Authority
SG
Singapore
Prior art keywords
vaccine
methods
porcine parvovirus
parvovirus
porcine
Prior art date
Application number
SG11201505930TA
Other languages
English (en)
Inventor
Arun V Iyer
Dianna M Murphy Jordan
Abby Rae Patterson
Michael B Roof
Eric Martin Vaughn
Joseph Gilbert Victoria
Callie Ann Visek
Original Assignee
Boehringer Ingelheim Vetmed
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmed filed Critical Boehringer Ingelheim Vetmed
Publication of SG11201505930TA publication Critical patent/SG11201505930TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/015—Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
SG11201505930TA 2013-02-15 2014-02-13 Porcine parvovirus 5b, methods of use and vaccine SG11201505930TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361765204P 2013-02-15 2013-02-15
US13/800,413 US20140234354A1 (en) 2013-02-15 2013-03-13 Porcine parvovirus 5b, methods of use and vaccine
PCT/US2014/016165 WO2014127084A1 (en) 2013-02-15 2014-02-13 Porcine parvovirus 5b, methods of use and vaccine

Publications (1)

Publication Number Publication Date
SG11201505930TA true SG11201505930TA (en) 2015-08-28

Family

ID=51351339

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201505930TA SG11201505930TA (en) 2013-02-15 2014-02-13 Porcine parvovirus 5b, methods of use and vaccine

Country Status (17)

Country Link
US (2) US20140234354A1 (ru)
EP (1) EP2956472A1 (ru)
JP (2) JP6215965B2 (ru)
KR (1) KR20150117272A (ru)
CN (1) CN104936975A (ru)
AR (1) AR094810A1 (ru)
AU (1) AU2014216337B2 (ru)
CA (1) CA2899942A1 (ru)
CL (1) CL2015002110A1 (ru)
CO (1) CO7461135A2 (ru)
EA (1) EA035320B1 (ru)
MX (1) MX366263B (ru)
PH (1) PH12015501721A1 (ru)
SG (1) SG11201505930TA (ru)
TW (1) TW201518506A (ru)
UA (1) UA118551C2 (ru)
WO (1) WO2014127084A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine
WO2018083154A1 (en) 2016-11-03 2018-05-11 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus
MY191895A (en) 2016-11-03 2022-07-18 Boehringer Ingelheim Vetmedica Gmbh Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof
KR102078879B1 (ko) * 2018-05-08 2020-02-19 대한민국(농림축산식품부 농림축산검역본부장) 돼지파보바이러스에 특이적인 단일클론항체 및 이의 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0117767A1 (en) 1983-01-07 1984-09-05 Mgi Pharma, Inc. Production of parvovirus subunit vaccines
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
US4567043A (en) 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4567042A (en) 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
AU4645697A (en) 1996-09-11 1998-04-02 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Aav4 vector and uses thereof
US20030049647A1 (en) 2001-02-22 2003-03-13 Bassil Dahiyat Use of nucleic acid libraries to create toxicological profiles
DK2504357T3 (en) * 2009-11-23 2017-10-23 Res Dev Foundation RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORT
DK2542260T3 (en) * 2010-03-05 2016-06-06 Intervet Int Bv Recombinantly weakening parvovirus
CN102382845B (zh) * 2011-10-14 2014-01-29 中国农业科学院生物技术研究所 猪细小病毒抗原的制备方法及其产品
US20140170180A1 (en) 2012-12-17 2014-06-19 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5a, methods of use and vaccine
US20140234354A1 (en) 2013-02-15 2014-08-21 Boehringer Ingelheim Vetmedica, Inc. Porcine parvovirus 5b, methods of use and vaccine

Also Published As

Publication number Publication date
TW201518506A (zh) 2015-05-16
EA035320B1 (ru) 2020-05-27
CO7461135A2 (es) 2015-11-30
JP2017192398A (ja) 2017-10-26
UA118551C2 (uk) 2019-02-11
CA2899942A1 (en) 2014-08-21
WO2014127084A1 (en) 2014-08-21
PH12015501721A1 (en) 2015-11-09
AU2014216337A1 (en) 2015-07-02
JP6215965B2 (ja) 2017-10-18
AR094810A1 (es) 2015-08-26
AU2014216337B2 (en) 2017-12-07
EP2956472A1 (en) 2015-12-23
JP2016509832A (ja) 2016-04-04
CL2015002110A1 (es) 2016-06-17
US20150283230A1 (en) 2015-10-08
MX366263B (es) 2019-07-04
KR20150117272A (ko) 2015-10-19
CN104936975A (zh) 2015-09-23
US9827306B2 (en) 2017-11-28
EA201500837A1 (ru) 2016-02-29
US20140234354A1 (en) 2014-08-21
MX2015010366A (es) 2015-10-29

Similar Documents

Publication Publication Date Title
HRP20170888T1 (hr) Spoj tubulisina, metode pripreme i primjena
HK1222778A1 (zh) 醫用裝置及使用該醫用裝置的方法
HK1223975A1 (zh) 含納米氣泡的組合物及其用途
SG11201510561QA (en) Patient interface and aspects thereof
SI2945647T1 (sl) Imunogeni peptidi WT-1 in postopki za uporabo le-teh
GB201317286D0 (en) Composition and Use
EP2985288A4 (en) PIGS PSEUDORABIESVIRUS, VACCINE COMPOSITION, AND METHOD OF PREPARATION AND USE THEREOF
GB201305277D0 (en) Novel combination and use
HK1221641A1 (zh) 疫苗組合物及使用方法
SG11201504805PA (en) Porcine parvovirus 5a, methods of use and vaccine
PL2988764T3 (pl) Kompozycje przeciwłupieżowe i sposoby ich zastosowania
IL244751A0 (en) Cyclic thianouracil-carboxamides and their use
EP2951208A4 (en) ANTI-CD83 ANTIBODIES AND THEIR USE
CL2015002110A1 (es) Parvovirus porcino 5b, métodos de uso y vacuna
GB201307989D0 (en) Novel combinations and use
GB201301979D0 (en) New composition and use thereof
SG11201601263WA (en) Recombinant microorganisms and methods of use thereof
GB2532383B (en) Set-delayed cement compositions comprising pumice and associated methods
EP2968557A4 (en) IMPROVING VACCINES
HK1216006A1 (zh) 反向遺傳學施馬倫貝格病毒疫苗組合物，和其使用方法
TH1501004575A (th) พอซีนพาโวไวรัส 5b, วิธีการใช้และวัคซีน
GB201322467D0 (en) Composition and use